Delving into the Latest Updates on Shanghai Yuesai Biotechnology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Yuesai Biotechnology is a company that specializes in creating cell therapy drugs using human pluripotent stem cell technology. They have developed a platform for preparing, cultivating, differentiating, and editing genes in human pluripotent stem cells, which they use to create therapies for neurodegenerative diseases, rare diseases, and tumors.

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Cardiovascular Diseases

Induced pluripotent stem cells (iPSC)

Neural stem cell therapy

Stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	4
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Induced pluripotent stem cells (iPSC)	2
Neural stem cell therapy	2
Cell therapy	1
TCR-T Cell therapy	1
Stem cell therapy	1

This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease. UX-DA001 manufactured from participant's own cells will differentiate into mature dopaminergic neurons after being transplanted into the brain of the participant.

Start Date01 Mar 2025

Sponsor / Collaborator

Shanghai Yuesai Biotechnology Co., Ltd.

CTR20244974

/ RecruitingPhase 1

UX-DA001注射液（人中脑多巴胺能神经前体细胞注射液）在原发性帕金森病患者中的探索性临床试验

[Translation] UX-DA001 injection (human midbrain dopaminergic neural precursor cell injection) exploratory clinical trial in patients with primary Parkinson's disease

主要目的：评估不同剂量组 UX-DA001 注射液细胞移植治疗原发性帕金森病（PD）患者的安全性和耐受性。次要目的：评估不同剂量组 UX-DA001 注射液在原发性 PD 患者脑内的植入、存活和增生情况；评估不同剂量组 UX-DA001 注射液对原发性 PD 患者运动症状的改善情况；评估不同剂量组 UX-DA001 注射液对原发性 PD 患者非运动症状及整体生活质量的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability of cell transplantation of UX-DA001 injection in different dose groups for the treatment of patients with primary Parkinson's disease (PD). Secondary objectives: To evaluate the implantation, survival and proliferation of UX-DA001 injection in different dose groups in the brain of patients with primary PD; To evaluate the improvement of motor symptoms of patients with primary PD by UX-DA001 injection in different dose groups; To evaluate the effects of UX-DA001 injection in different dose groups on non-motor symptoms and overall quality of life of patients with primary PD.

Start Date21 Feb 2025

Sponsor / Collaborator

Shanghai Yuesai Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai Yuesai Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Yuesai Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Yuesai Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Yuesai Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

1

Preclinical

Phase 1 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

UX-DA001	Primary Parkinson's disease More	Phase 1
UX-EP001	Epilepsy More	Preclinical
UX- SP001	Spinal Cord Injuries More	Discovery
UX-UD	-	Discovery
UX-HIE001	Hypoxia-Ischemia, Brain More	Discovery